Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study
Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Maximilian Stahl(Harvard University), Vinod Pullarkat(City of Hope), Jorge Ramos(Seagen (United States)), Sylvain Garciaz(Centre National de la Recherche Scientifique), Guillaume Berton(Hôpital de la Conception), Ibrahim Aldoss(City of Hope), Shai Shimony(Twitter (United States)), Evan C. Chen(Dana-Farber Cancer Institute), Rebecca P. Bystrom(Dana-Farber Cancer Institute), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Brian Ball(City Of Hope National Medical Center), Eva J. Schaefer(Dana-Farber Cancer Institute), Guido Marcucci(City of Hope), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Amer M. Zeidan(Yale Cancer Center), Richard M. Stone(Dana-Farber Cancer Institute), R. Coleman Lindsley(Harvard University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Rory M. Shallis(Smilow Cancer Hospital), Donna Neuberg(Otsuka (Japan)), Yiwen Liu(University of Arizona), Anthony S. Stein(University of Hohenheim)
Cited by 9
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k